SCHEMBL19065106

SCHEMBL19065106

O=S(=O)(Nc1cccc(Br)c1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.64
HSD17B2 P37059 2/20 0.61
CDK1 P06493 2/20 0.60
CCNB1 P14635 2/20 0.60
CCNA2 P20248 2/20 0.60
CDK2 P24941 2/20 0.60
CDK7 P50613 2/20 0.60
CCNH P51946 2/20 0.60
CCNA1 P78396 2/20 0.60
FFAR1 O14842 1/20 0.60
FFAR4 Q5NUL3 1/20 0.60
KMT2A Q03164 2/20 0.60
NR3C1 P04150 1/20 0.59
PGR P06401 1/20 0.59
AR P10275 1/20 0.59
ESR2 Q92731 1/20 0.59
GAA P10253 2/20 0.58
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
MMP1 P03956 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22441723 0.94 CDK1 (0.64) TSHRHSD17B2CDK1CCNB1CCNA2
SCHEMBL22441656 0.87 FFAR1 (0.62) HSD17B2CDK1CCNB1CCNA2CDK2
SCHEMBL3762909 0.85 PGR (0.77) TSHRHSD17B2CDK1CCNB1CCNA2
SCHEMBL14433749 0.85 HSD17B2 (0.66) HSD17B2PGRPTPN2PTPN1PTPN5
SCHEMBL7571567 0.84 HSD17B2 (0.63) TSHRHSD17B2CDK1CCNB1CCNA2
SCHEMBL22441798 0.84 PGR (0.60) TSHRHSD17B2KMT2ANR3C1PGR
SCHEMBL121452 0.82 CDK1 (0.76) TSHRHSD17B2CDK1CCNB1CCNA2
SCHEMBL7568254 0.82 MEN1 (0.57) TSHRHSD17B2KMT2ANR3C1PGR
SCHEMBL7825221 0.82 TSHR (0.62) TSHRHSD17B2CDK1CCNB1CCNA2
SCHEMBL5730534 0.80 IL1RN (0.66) HSD17B2KMT2APGRGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200299282-A1 COMPOUNDS AND METHODS FOR TREATING CANCER ANTIDOTE IP HOLDINGS LLC (US) 2020-09-24 US disclosed
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-01-29 US disclosed
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-01-29 US disclosed
EP-3209641-A2 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF ROR AND THE TREATEMENT OF DISEASE Lycera Corporation (US) 2017-08-30 EP disclosed
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-07-06 US disclosed
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-07-06 US disclosed
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease RORC, RORB, RORA TSHR 549/4885HSD17B2 69/4885CDK1 1858/4885
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORB, RORA, RORC TSHR 477/4885HSD17B2 109/4885CDK1 1591/4885
US-20200299282-A1 COMPOUNDS AND METHODS FOR TREATING CANCER VHL, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 TSHR 4822/4885HSD17B2 2476/4885CDK1 1583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.